Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

D.M.F. Claassens, P.W.M. van Dorst, G.J.A. Vos, T.O. Bergmeijer, R.S. Hermanides, A.W.J.V. Hof, P. van der Harst, E. Barbato, C. Morisco, R.M.T.J. Gin, F.W. Asselbergs, A. Mosterd, J.P.R. Herrman, W.J.M. Dewilde, M.J. Postma, V.H.M. Deneer, J.M. ten Berg*, C. Boersma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Number of pages12
JournalAmerican Journal of Cardiovascular Drugs
DOIs
Publication statusE-pub ahead of print - 7 Sep 2021

Keywords

  • ACUTE CORONARY SYNDROME
  • ST-SEGMENT ELEVATION
  • ANTIPLATELET THERAPY
  • TASK-FORCE
  • AMERICAN-COLLEGE
  • CLOPIDOGREL
  • TICAGRELOR
  • GUIDELINES
  • PRASUGREL
  • SELECTION

Cite this